Michael D Lewis

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2174484/publications.pdf

Version: 2024-02-01

58 papers

3,378 citations

33 h-index 55 g-index

68 all docs 68
docs citations

68 times ranked

2761 citing authors

#	Article	IF	CITATIONS
1	Bioluminescence imaging of chronic <scp> <i>T</i> </scp> <i>rypanosoma cruzi</i> infections reveals tissueâ€specific parasite dynamics and heart disease in the absence of locally persistent infection. Cellular Microbiology, 2014, 16, 1285-1300.	2.1	210
2	Genome-Scale Multilocus Microsatellite Typing of Trypanosoma cruzi Discrete Typing Unit I Reveals Phylogeographic Structure and Specific Genotypes Linked to Human Infection. PLoS Pathogens, 2009, 5, e1000410.	4.7	180
3	The genotype distribution of the XRCC1gene indicates a role for base excision repair in the development of therapy-related acute myeloblastic leukemia. Blood, 2002, 100, 3761-3766.	1.4	161
4	Shotgun Sequencing Analysis of Trypanosoma cruzi I Sylvio X10/1 and Comparison with T. cruzi VI CL Brener. PLoS Neglected Tropical Diseases, 2011 , 5 , $e984$.	3.0	129
5	Limited Ability of Posaconazole To Cure both Acute and Chronic Trypanosoma cruzi Infections Revealed by Highly Sensitive <i>In Vivo</i> Imaging. Antimicrobial Agents and Chemotherapy, 2015, 59, 4653-4661.	3.2	124
6	Genome and Phylogenetic Analyses of Trypanosoma evansi Reveal Extensive Similarity to T. brucei and Multiple Independent Origins for Dyskinetoplasty. PLoS Neglected Tropical Diseases, 2015, 9, e3404.	3.0	124
7	Trypanosoma cruzi Ilc: Phylogenetic and Phylogeographic Insights from Sequence and Microsatellite Analysis and Potential Impact on Emergent Chagas Disease. PLoS Neglected Tropical Diseases, 2009, 3, e510.	3.0	118
8	Recent, Independent and Anthropogenic Origins of Trypanosoma cruzi Hybrids. PLoS Neglected Tropical Diseases, 2011, 5, e1363.	3.0	117
9	Genotyping of Trypanosoma cruzi: Systematic Selection of Assays Allowing Rapid and Accurate Discrimination of All Known Lineages. American Journal of Tropical Medicine and Hygiene, 2009, 81, 1041-1049.	1.4	114
10	Comparative phylogeography of Trypanosoma cruzi TCIIc: New hosts, association with terrestrial ecotopes, and spatial clustering. Infection, Genetics and Evolution, 2009, 9, 1265-1274.	2.3	105
11	Multiple Mitochondrial Introgression Events and Heteroplasmy in Trypanosoma cruzi Revealed by Maxicircle MLST and Next Generation Sequencing. PLoS Neglected Tropical Diseases, 2012, 6, e1584.	3.0	104
12	Flow cytometric analysis and microsatellite genotyping reveal extensive DNA content variation in Trypanosoma cruzi populations and expose contrasts between natural and experimental hybrids. International Journal for Parasitology, 2009, 39, 1305-1317.	3.1	101
13	Contemporary cryptic sexuality in <i>Trypanosoma cruzi</i> . Molecular Ecology, 2012, 21, 4216-4226.	3.9	96
14	Multilocus Sequence Typing (MLST) for Lineage Assignment and High Resolution Diversity Studies in Trypanosoma cruzi. PLoS Neglected Tropical Diseases, 2011, 5, e1049.	3.0	94
15	A New Experimental Model for Assessing Drug Efficacy against Trypanosoma cruzi Infection Based on Highly Sensitive In Vivo Imaging. Journal of Biomolecular Screening, 2015, 20, 36-43.	2.6	91
16	Putting Infection Dynamics at the Heart of Chagas Disease. Trends in Parasitology, 2016, 32, 899-911.	3.3	83
17	Expanding the toolbox for Trypanosoma cruzi: A parasite line incorporating a bioluminescence-fluorescence dual reporter and streamlined CRISPR/Cas9 functionality for rapid in vivo localisation and phenotyping. PLoS Neglected Tropical Diseases, 2018, 12, e0006388.	3.0	79
18	Host and parasite genetics shape a link between <i>Trypanosoma cruzi</i> infection dynamics and chronic cardiomyopathy. Cellular Microbiology, 2016, 18, 1429-1443.	2.1	78

#	Article	IF	CITATIONS
19	Visualisation of Leishmania donovani Fluorescent Hybrids during Early Stage Development in the Sand Fly Vector. PLoS ONE, 2011, 6, e19851.	2.5	77
20	Development of Trypanosoma cruzi in vitro assays to identify compounds suitable for progression in Chagas' disease drug discovery. PLoS Neglected Tropical Diseases, 2018, 12, e0006612.	3.0	76
21	Nitroheterocyclic drugs cure experimental Trypanosoma cruzi infections more effectively in the chronic stage than in the acute stage. Scientific Reports, 2016, 6, 35351.	3.3	72
22	Extraordinary Trypanosoma cruzi diversity within single mammalian reservoir hosts implies a mechanism of diversifying selection. International Journal for Parasitology, 2011, 41, 609-614.	3.1	69
23	The midgut microbiota plays an essential role in sand fly vector competence for <i>Leishmania major < /i>. Cellular Microbiology, 2017, 19, e12755.</i>	2.1	67
24	Comparative genomic analysis of human infective Trypanosoma cruzi lineages with the bat-restricted subspecies T. cruzi marinkellei. BMC Genomics, 2012, 13, 531.	2.8	57
25	Highly Sensitive In Vivo Imaging of Trypanosoma brucei Expressing "Red-Shifted―Luciferase. PLoS Neglected Tropical Diseases, 2013, 7, e2571.	3.0	56
26	Candidate targets for Multilocus Sequence Typing of Trypanosoma cruzi: Validation using parasite stocks from the Chaco Region and a set of reference strains. Infection, Genetics and Evolution, 2012, 12, 350-358.	2.3	54
27	Resolution of multiclonal infections of Trypanosoma cruzi from naturally infected triatomine bugs and from experimentally infected mice by direct plating on a sensitive solid medium. International Journal for Parasitology, 2007, 37, 111-120.	3.1	50
28	North American import? Charting the origins of an enigmatic Trypanosoma cruzi domestic genotype. Parasites and Vectors, 2012, 5, 226.	2.5	48
29	Biological factors that impinge on Chagas disease drug development. Parasitology, 2017, 144, 1871-1880.	1.5	45
30	Analysis of molecular diversity of the Trypanosoma cruzi trypomastigote small surface antigen reveals novel epitopes, evidence of positive selection and potential implications for lineage-specific serology. International Journal for Parasitology, 2010, 40, 921-928.	3.1	42
31	Genome-wide mutagenesis and multi-drug resistance in American trypanosomes induced by the front-line drug benznidazole. Scientific Reports, 2017, 7, 14407.	3.3	41
32	<i>In Vivo</i> Analysis of Trypanosoma cruzi Persistence Foci at Single-Cell Resolution. MBio, 2020, 11,	4.1	40
33	Development of Peptide-Based Lineage-Specific Serology for Chronic Chagas Disease: Geographical and Clinical Distribution of Epitope Recognition. PLoS Neglected Tropical Diseases, 2014, 8, e2892.	3.0	37
34	Imaging the development of chronic Chagas disease after oral transmission. Scientific Reports, 2018, 8, 11292.	3.3	36
35	Molecular Epidemiologic Source Tracking of Orally Transmitted Chagas Disease, Venezuela. Emerging Infectious Diseases, 2013, 19, 1098-1101.	4.3	33
36	Challenges in Chagas Disease Drug Development. Molecules, 2020, 25, 2799.	3.8	33

#	Article	IF	CITATIONS
37	Molecular Diversity of Trypanosoma cruzi Detected in the Vector Triatoma protracta from California, USA. PLoS Neglected Tropical Diseases, 2016, 10, e0004291.	3.0	33
38	Multilocus sequence and microsatellite identification of intra-specific hybrids and ancestor-like donors among natural Ethiopian isolates of Leishmania donovani. International Journal for Parasitology, 2014, 44, 751-757.	3.1	31
39	The Trypanosoma cruzi Vitamin C Dependent Peroxidase Confers Protection against Oxidative Stress but Is Not a Determinant of Virulence. PLoS Neglected Tropical Diseases, 2015, 9, e0003707.	3.0	28
40	Repeat-Driven Generation of Antigenic Diversity in a Major Human Pathogen,ÂTrypanosoma cruzi. Frontiers in Cellular and Infection Microbiology, 2021, 11, 614665.	3.9	25
41	Intracellular DNA replication and differentiation of Trypanosoma cruzi is asynchronous within individual host cells in vivo at all stages of infection. PLoS Neglected Tropical Diseases, 2020, 14, e0008007.	3.0	23
42	Assessing the Effectiveness of Curative Benznidazole Treatment in Preventing Chronic Cardiac Pathology in Experimental Models of Chagas Disease. Antimicrobial Agents and Chemotherapy, 2018, 62,	3.2	22
43	Hostâ€parasite dynamics in Chagas disease from systemic to hyperâ€local scales. Parasite Immunology, 2021, 43, e12786.	1.5	19
44	Apolipoprotein L1 Variant Associated with Increased Susceptibility to Trypanosome Infection. MBio, 2016, 7, e02198-15.	4.1	18
45	Fatal progression of experimental visceral leishmaniasis is associated with intestinal parasitism and secondary infection by commensal bacteria, and is delayed by antibiotic prophylaxis. PLoS Pathogens, 2020, 16, e1008456.	4.7	17
46	Hosts and vectors of <i>Trypanosoma cruzi</i> li> discrete typing units in the Chagas disease endemic region of the Paraguayan Chaco. Parasitology, 2017, 144, 884-898.	1.5	16
47	Molecular Genotyping of Trypanosoma cruzi for Lineage Assignment and Population Genetics. Methods in Molecular Biology, 2015, 1201, 297-337.	0.9	15
48	Exploiting Genetically Modified Dual-Reporter Strains to Monitor Experimental Trypanosoma cruzi Infections and Host-Parasite Interactions. Methods in Molecular Biology, 2019, 1955, 147-163.	0.9	15
49	Local association of Trypanosoma cruzi chronic infection foci and enteric neuropathic lesions at the tissue micro-domain scale. PLoS Pathogens, 2021, 17, e1009864.	4.7	13
50	Drug-cured experimental Trypanosoma cruziÂinfections confer long-lasting and cross-strain protection. PLoS Neglected Tropical Diseases, 2020, 14, e0007717.	3.0	12
51	Incomplete Recruitment of Protective T Cells Is Associated with Trypanosoma cruzi Persistence in the Mouse Colon. Infection and Immunity, 2022, 90, IAI0038221.	2.2	9
52	Microevolution of Trypanosoma cruzi reveals hybridization and clonal mechanisms driving rapid genome diversification. ELife, 2022, 11 , .	6.0	9
53	Culture-free genome-wide locus sequence typing (GLST) provides new perspectives on Trypanosoma cruzi dispersal and infection complexity. PLoS Genetics, 2020, 16, e1009170.	3.5	7
54	Bioluminescent: Fluorescent Trypanosoma cruzi Reporter Strains as Tools for Exploring Chagas Disease Pathogenesis and Drug Activity. Current Pharmaceutical Design, 2021, 27, 1733-1740.	1.9	3

#	Article	IF	CITATIONS
55	Experimental and Natural Recombination in Trypanosoma cruzi. , 2010, , 459-474.		2
56	Reply to "Drug Susceptibility of Genetically Engineered Trypanosoma cruzi Strains and Sterile Cure in Animal Models as a Criterion for Potential Clinical Efficacy of Anti-T. cruzi Drugs― Antimicrobial Agents and Chemotherapy, 2015, 59, 7925-7925.	3.2	2
57	Genetic Exchange in Trypanosomatids and Its Relevance to Epidemiology. , 2011, , 581-605.		1
58	Highly Sensitive Bioluminescence Imaging Models for Chagas Disease Drug Discovery. Proceedings (mdpi), 2017, 1, 676.	0.2	0